Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022
Share
Pharma Mar, S.A. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EUR 34.94 million compared to EUR 34.41 million a year ago. Revenue was EUR 53.19 million compared to EUR 51.26 million a year ago. Net income was EUR 21.98 million compared to EUR 24.18 million a year ago.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
